ICON Public Limited (NASDAQ:ICLR) Given Average Rating of “Buy” by Brokerages

Shares of ICON Public Limited (NASDAQ:ICLR) have been assigned a consensus recommendation of “Buy” from the ten ratings firms that are presently covering the firm, MarketBeat Ratings reports. Ten equities research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have covered the stock in the last year is $352.56.

Several research firms have weighed in on ICLR. The Goldman Sachs Group assumed coverage on ICON Public in a research note on Thursday, June 6th. They issued a “buy” rating and a $370.00 price target for the company. Truist Financial boosted their price target on shares of ICON Public from $367.00 to $383.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Robert W. Baird raised their price objective on ICON Public from $367.00 to $376.00 and gave the company an “outperform” rating in a research report on Monday, July 8th. Barclays reduced their target price on shares of ICON Public from $355.00 to $350.00 and set an “overweight” rating on the stock in a report on Friday, July 26th. Finally, Evercore ISI lowered their price target on shares of ICON Public from $350.00 to $330.00 and set an “outperform” rating for the company in a report on Friday, April 26th.

ICON Public Stock Down 0.0 %

ICLR stock opened at $312.93 on Monday. The business’s 50-day moving average price is $322.07 and its 200-day moving average price is $313.56. The stock has a market cap of $25.82 billion, a P/E ratio of 38.07, a PEG ratio of 1.46 and a beta of 1.22. The company has a quick ratio of 1.31, a current ratio of 1.31 and a debt-to-equity ratio of 0.36. ICON Public has a twelve month low of $221.20 and a twelve month high of $347.72.

ICON Public (NASDAQ:ICLR) last announced its quarterly earnings data on Wednesday, July 24th. The medical research company reported $3.75 EPS for the quarter, beating the consensus estimate of $3.68 by $0.07. ICON Public had a net margin of 8.57% and a return on equity of 12.06%. The firm had revenue of $2.10 billion for the quarter, compared to the consensus estimate of $2.14 billion. During the same period last year, the firm earned $2.96 EPS. The company’s revenue was up 4.1% on a year-over-year basis. On average, equities research analysts forecast that ICON Public will post 14.54 EPS for the current year.

Hedge Funds Weigh In On ICON Public

Institutional investors have recently made changes to their positions in the company. Livelsberger Financial Advisory bought a new position in ICON Public during the 4th quarter worth about $29,000. Pinnacle Bancorp Inc. boosted its stake in shares of ICON Public by 110.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 105 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 55 shares in the last quarter. Riverview Trust Co bought a new position in shares of ICON Public during the first quarter valued at approximately $31,000. GAMMA Investing LLC purchased a new position in ICON Public during the fourth quarter valued at approximately $37,000. Finally, Ashton Thomas Private Wealth LLC bought a new position in ICON Public in the second quarter worth approximately $54,000. Hedge funds and other institutional investors own 95.61% of the company’s stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.